in ,

Jaypirca (Pirtobrutinib): Uses, Dose, MOA, Side effects

Jaypirca (Pirtobrutinib)


Jaypirca (Pirtobrutinib) is a medication that is used to treat mantle cell lymphoma (MLC) that is relapsed or irresponsive to other treatments. It is also safe and effective to be used in children.

Brand Name: Jaypirca

Medical Name: Pirtobrutinib

Class: BTK (Bruton’s Tyrosine Kinase) Inhibitor

FDA-Approval Date: 27th January 2023

Primary Indication: Refractory or relapsed Mantle Cell Lymphoma

You may also like to read:

Jaypirca (Pirtobrutinib) FDA-Approved Indications:

JAYPIRCA is a Bruton’s Tyrosine Kinase Inhibitor (BTK-Inhibitor). It has been approved by the FDA for treating mantle cell lymphoma in patients who have not responded adequately to previous therapies including a BTK inhibitor and at least two first-line of chemotherapeutic drugs.

It is indicated for the treatment of relapsed cases or refractory cases of mantle cell lymphoma.

Jaypirca (Pirtobrutinib) Dose Recommendation:

The usual recommended dose is 200 mg orally once a day. The treatment is continued until the toxic effects of the drugs are observed or the disease is noted to progress despite the treatment.

The tablets should be swallowed whole with water. Avoid cutting, crushing, or chewing them. The drug should be taken daily at the same time of the day without regard to meals or food.

If a person forgets to take the dose at the scheduled time, it should be taken immediately. However, if more than 12 hours have passed, skip the dose and wait for the next dose.

You may also like to read:

Dose modification due to side effects occurrence:

Adverse Reaction

Dosage Modification

First Occurrence Interrupt JAYPIRCA until the adverse reaction is resolved or reduced to Grade 1 or baseline.

Restart the dose at the usual recommended dose of 200 mg once daily.

Second Occurrence Withhold the treatment until the side effects have resolved or improved to at least Grade 1.

Restart the dose at half the usual recommended dose (100 mg once daily).

Third Occurrence Stop the treatment until the side effects have resolved or improved to Grade 1.

Restart the dose at a much lower dose i.e. 50 mg once daily.

Fourth Occurrence Discontinue the treatment permanently.

Lymphocytosis can occur however, in asymptomatic patients, adjusting the dose is not recommended.

You may also like to read:

Dosage modifications for JAYPIRCA in specific situations:


Dosage Modification

Severe Renal Impairment (eGFR 15-29 mL/min) Reduce the dose to 100 mg orally once daily if the current dose is 200 mg once daily, otherwise, reduce to 50 mg. Discontinue the treatment if the current dose is 50 mg once daily.
Mild to Moderate Renal Impairment (eGFR 30-89 mL/min) No modification recommended
Concomitant use with Strong CYP3A Inhibitors Avoid it if possible. If unavoidable, reduce the JAYPIRCA dose by 50 mg. Interrupt JAYPIRCA treatment if currently taking 50 mg once daily.

Resume the previous dose after 5 half-lives of the CYP3A inhibitor.

Concomitant use with Strong or Moderate CYP3A Inducers Avoid concomitant use with strong or moderate CYP3A inducers.

However, if one can not avoid it, increase the dose to 300 mg.

For current dosages of 50 mg or 100 mg once daily, increase by 50 mg.

You may also like to read:

Jaypirca Dose form and strength:




50 mg Blue, arc-triangle shaped “Lilly 50” on one side, “6902” on other
100 mg Blue, round “Lilly 100” on one side, “7026” on other

Contraindications to Pirtobrutinib (Jaypirca):

No contraindication is given in the FDA prescribing information.

The warnings and precautions for JAYPIRCA are listed in the table below:

Safety Information


Infections Consider prophylaxis in patients at increased risk.

Monitor for the clinical features of infection and treat promptly with appropriate antibiotics.

In severe infection, the treatment may be discontinued.

Hemorrhage Consider the risk of bleeding and monitor (for bleeding) in patients on antithrombotic drugs.

The treatment may be discontinued in severe cases and after major surgery.

Cytopenias Monitor for cytopenias and adjust or discontinue the treatment if required.
Atrial Fibrillation/Flutter Monitor for arrhythmias. Educate the patients to report palpitations and shortness of breath.

In severe cases, the treatment may be discontinued.

Second Primary Malignancies Advise patients to use sunscreens. Monitor for second primary malignancies.
Embryo-Fetal Toxicity The drug is toxic to the fetus. Ensure effective contraception during the treatment and one week after the treatment.
You may also like to read:

Side effects of Jaypirca (Pirtobrutinib):

Side Effects



Infections Fatal and serious infections and sepsis can occur in patients with febrile neutropenia
Hemorrhage Fatal and serious bleeding including major bleeding episodes can occur.
Cytopenias Grade 3 or 4 cytopenias
Atrial Fibrillation and Atrial Flutter Atrial fibrillation and atrial flutter
Secondary Malignancies Solid tumors and melanoma


Infections Grade 3 or higher infections especially pneumonia
Hemorrhage Bleeding of any grade, excluding bruising and petechiae
Cytopenias Neutropenia, anemia, thrombocytopenia
Atrial Fibrillation and Atrial Flutter Atrial fibrillation or flutter

Less Common

Infections Opportunistic infections
Hemorrhage Major bleeding especially with the concomitant use of antithrombotic drugs
Cytopenias Grade 4 neutropenia and thrombocytopenia
Embryo-Fetal Toxicity Fetal harm

Side effects experience in clinical trials:

Adverse Reactions (by System Organ Class) Rate (%)
Neutropenia 41
Anemia 37
Thrombocytopenia 27
Tiredness 27
Skeletal pain 26
Lymphocytopenia 24
Bruising 20
Diarrhea 20

Drug interactions:

Drugs Effect on JAYPIRCA Recommendation
Strong CYP3A Inhibitors Increases Jaypirca’s systemic exposure Avoid concomitant use of strong CYP3A inhibitors.

May reduce the dose of JAYPIRCA if the strong CYP3A4 inhibitor can not be avoided.

Strong or Moderate CYP3A Inducers Decreases Jaypirca’s systemic exposure Avoid concomitant use of strong or moderate CYP3A inducers. If moderate CYP3A inducers are unavoidable, increase the JAYPIRCA dosage
Effect of JAYPIRCA on Other Drugs P-gp inhibitor, moderate CYP2C8 and BCRP inhibitor, and weak CYP2C19 and CYP3A inhibitor Increases plasma concentrations of sensitive P-gp, CYP2C8, BCRP, CYP2C19, or CYP3A substrates
Risks Associated with Increased Concentrations of Substrates This may increase the risk of adverse reactions Follow recommendations for sensitive CYP2C8, CYP2C19, CYP3A, P-gp, or BCRP substrates provided in their approved product labeling
You may also like to read:

Use of Jayprica in specific populations:

Category Description
Pediatric Use Not studied in children.
Geriatric Use Data is limited however, older people are at an increased risk of developing side effects.
Renal Impairment No need to adjust the dose for mild and moderate renal impairment. In severe renal impairment, reduce the dose.
Hepatic Impairment Dosage adjustment is not recommended in patients with liver disease of any severity.
Risk Summary Jaypirca is toxic to the fetus. Pregnancy should be avoided using effective contraception during the treatment and for at least one week after the last dose.
Risk Summary No information is available. Breastfeeding is not recommended during the treatment and at least for a week after the last dose.
Females and Males of Reproductive Potential
Pregnancy Testing Test for pregnancy in females of reproductive ages before initiating the treatment.
Contraception Effective contraception is recommended during the treatment for at least one week after the last dose.
You may also like to read:

Mechanism of Action (MOA) of Pirtobrutinib (Jaypirca):

Pirtobrutinib belongs to the class of medicines called Bruton’s tyrosine kinase (BTK) inhibitors.

BTK is an important signaling protein for the B-cell antigen receptor (BCR) and cytokine receptor pathways.

BTK is a signaling protein that activates pathways that are essential for B-cell functions such as proliferation, trafficking, chemotaxis, and adhesion.

Pirtobrutinib targets both the normal BTK and BTK with C481 mutations resulting in the inhibition of BTK kinase activation of B cells. Hence, it inhibits BTK-mediated functions of B-cells CD69 expression and proliferation.

Cardiac Electrophysiology:

No significant effect on the QTc interval.



Dose Proportionality Pirtobrutinib exposure (AUC) and Cmax increase proportionally
Steady State 5 days
Absolute bioavailability 85.5% (range 75.9% to 90.9%).
Peak plasma concentration 2 hours
Effect of Food A high-fat meal decreased the Cmax of Pirtobrutinib by 23% and delayed the Tmax by 1 hour.
Protein binding 96%.
Elimination 19 hours
  • CYP3A4
  • Direct glucuronidation by UGT1A8 and UGT1A9.
  • Feces: 37% (18% unchanged) and
  • Urine: 57% (10% unchanged).
You may also like to read:

Clinical studies:

Aspect Details
Study Name BRUIN (NCT03740529) [Ref]
Participants The study enrolled 120 patients with mantle cell lymphoma who had been previously treated with Bruton’s tyrosine kinase (BTK) inhibitors.

Those with active CNS lymphoma, who had undergone allogeneic HSCT, or had received CAR) T-cell therapy within 60 days were excluded from the study.

Treatment Enrolled patients were given JAYPIRCA orally at a dose of 200 mg once daily.
Outcome Overall response rate (ORR) and duration of response (DOR) were evaluated based on 2014 Lugano criteria by an independent review committee (IRC)
Results The median age of patients was 71 years (79% were male)

ORR was 66.7% (80/120) with a complete response (CR) rate of 28.3% (34/120) and partial response (PR) rate of 38.3% (46/120);

the median duration of response was 19.5 months.

Conclusion: In patients with MCL who had previously been treated with a BTK inhibitor, JAYPIRCA demonstrated an ORR of 66.7% with a median duration of response of 19.5 months.

You may also like to read:

Patient counseling information:


Counseling Information

Patient Labeling Patients should read the FDA handout.
Infections Serious infections can occur during the treatment. Patients should report any signs of infection instantly
Bleeding Bleeding can occur. During major surgeries, the treatment may be temporarily stopped.
Cytopenias Frequent monitoring of blood counts is important to identify marrow toxicity earlier.
Atrial arrhythmia Atrial fibrillation and flutter have been reported during the treatment. patients should be asked to report symptoms of shortness of breath and palpitations.
Second Primary Malignancies There is a risk of skin cancer and other solid tumors. Patients should limit sun exposure and use sunscreens. Monitoring for solid tumors is also important.
Embryo-Fetal Toxicity The drug is toxic to the fetus. Effective contraception should be used during the treatment and at least one week after the last dose.
Lactation Breastfeeding is not recommended until one week after the last dose.
Administration The drug should be taken daily at the scheduled time. Crushing the tablet, chewing, or cutting is not recommended. In addition, one should not make up for a missed dose if more than 12 hours have passed.
You may also like to read:

What do you think?

Written by Dr. Ahmed

I am Dr. Ahmed (MBBS; FCPS Medicine), an Internist and a practicing physician. I am in the medical field for over fifteen years working in one of the busiest hospitals and writing medical posts for over 5 years.

I love my family, my profession, my blog, nature, hiking, and simple life. Read more about me, my family, and my qualifications

Here is a link to My Facebook Page. You can also contact me by email at or at My Twitter Account
You can also contact me via WhatsApp 🙏

Zelnorm (Tegaserod)

Zelnorm (Tegaserod) for IBS-C

Ozempic and Depression wrongly labeled Ozempic injections

Ozempic and Depression: My Choice of Antidepressants